Equities

abrdn Life Sciences Investors

HQL:NYQ

abrdn Life Sciences Investors

Actions
FinancialsClosed End Investments
  • Price (USD)13.79
  • Today's Change-0.04 / -0.29%
  • Shares traded116.70k
  • 1 Year change+17.06%
  • Beta0.6827
Data delayed at least 15 minutes, as of Nov 22 2024 21:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

abrdn Life Sciences Investors (the Fund), formerly Tekla Life Sciences Investors, is a non-diversified closed-end management investment company. The Fund's investment objective is long-term capital appreciation through investment in United States and foreign companies in the life sciences industry, including biotechnology, pharmaceutical, diagnostics, managed healthcare and medical equipment, hospitals, healthcare information technology and services, devices and supplies, and agriculture and environmental management. The Fund invests primarily in securities of public and private companies, which have the potential for above-average growth. The Fund invests up to 20% of its net assets in securities of foreign issuers, expected to be located primarily in Western Europe, Canada and Japan, and securities of United States issuers that are traded primarily in foreign markets. The Fund's investment adviser is abrdn Inc.

  • Revenue in USD (TTM)3.63m
  • Net income in USD38.81m
  • Incorporated1992
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
KKR Income Opportunities Fund58.96m65.69m364.23m--5.020.9902--6.182.672.672.4813.560.1047--6.31--11.662.7612.232.8475.7579.12111.4232.75----0.2908212.9538.755.14186.7813.36---1.37
Source Capital Inc21.16m50.00m364.42m0.007.270.9684--17.236.116.112.5945.890.0575--5.79--13.588.3913.718.5285.4277.71236.35242.66----0.0066.8249.0918.97298.03----20.76
John Hancock Preferred Income Fund II-100.00bn-100.00bn367.84m--------------------------------------------------------------
Abrdn Global Premier Properties Fund15.09m-9.19m368.96m----1.15--24.44-0.1076-0.10760.17673.760.0352--4.62---2.14---2.17--36.36---60.85----0.40360.2175---12.25--91.44------
Virtus Total Return Fund Inc27.23m25.29m371.87m0.0014.800.9501--13.660.4070.4070.41796.340.0443--7.52--4.121.104.141.1134.2349.6992.8834.70----0.3007707.0738.3913.07-364.54-----6.84
Stellus Capital Investment Corp107.14m48.64m373.40m0.007.071.02--3.491.951.954.3113.550.1147--102.94--5.202.985.293.0445.7345.4145.3931.16----0.6109111.7040.9214.7220.99-7.72--2.07
Churchill Capital Corp IX-100.00bn-100.00bn373.96m--------------------------------------------------------------
Western Asst High Incm Opprtnty Fnd Inc.-100.00bn-100.00bn375.64m--------------------------------------------------------------
Blackrock Energy and Resources Trust-100.00bn-100.00bn376.27m0.00------------------------------------------------------------
Eaton Vance Senior Floating-Rate Trust-100.00bn-100.00bn376.69m--------------------------------------------------------------
abrdn Life Sciences Investors3.63m38.81m378.26m--9.750.8576--104.071.421.420.132916.130.0083--59.13--8.871.548.991.56-36.65-68.311,067.62238.14----0.00514.0115.8911.99121.37-4.85----
ASA Gold and Precious Metals Ltd2.36m62.61m385.80m0.0017.760.9434--163.731.131.130.084321.200.0062--7.53--16.537.7816.547.7891.2487.152,657.321,254.26----0.001.36-6.108.08106.24------
BNY Mellon Strategic Municipals Inc28.16m20.18m386.83m--19.170.8873--13.730.32390.32390.45217.000.0435--12.35--3.330.0613.370.061271.9588.5376.611.46----0.3028---5.22-6.53101.61-10.53---9.46
Guggenhm Txble Mcpl Bnd & Invt Gd Dt Trt-100.00bn-100.00bn387.40m--------------------------------------------------------------
DWS Municipal Income Trust27.29m14.12m387.81m--27.450.988927.4714.210.36070.36070.697110.010.0438--31.22--2.270.63482.270.636249.5570.6951.7416.47----0.3433402.176.42-3.30116.94-----12.45
Data as of Nov 22 2024. Currency figures normalised to abrdn Life Sciences Investors's reporting currency: US Dollar USD

Institutional shareholders

26.07%Per cent of shares held by top holders
HolderShares% Held
Saba Capital Management LPas of 30 Sep 20243.43m12.54%
Penserra Capital Management LLCas of 30 Sep 2024776.00k2.84%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024478.53k1.75%
Karpus Management, Inc.as of 30 Sep 2024468.60k1.71%
Sit Investment Associates, Inc.as of 30 Sep 2024417.06k1.53%
Needham Investment Management LLCas of 30 Sep 2024352.72k1.29%
1607 Capital Partners LLCas of 30 Sep 2024349.50k1.28%
Flagship Harbor Advisors LLCas of 30 Sep 2024312.94k1.14%
Allspring Global Investments LLCas of 30 Sep 2024280.30k1.03%
AQR Arbitrage LLCas of 30 Sep 2024263.28k0.96%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.